Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Bioavailability of ODM-201 in Healthy Males
NCT02418650Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Mar 2015
- Primary completion
- May 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by Orion Corporation. Primary endpoint: Amount and cumulative amount of 14C-ODM-201 dose excreted in urine and faeces up to 14 days. Started Mar 2015; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02418650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418650.